Apoptosis pathway-targeted drugs - From the bench to the clinic

Jeff Cummings, Tim H. Ward, Malcolm Ranson, Caroline Dive

Research output: Contribution to journalArticlepeer-review


It is an exciting time for cancer researchers in the field of apoptotic cell death. The avalanche of discoveries over the past decade or so regarding how apoptosis is regulated begins to be exploited for therapeutic benefit as the first apoptosis-targeted drugs enter early clinical trials. This chapter provides a selective review on the development of such drugs. We also outline issues regarding the regulation and design of early clinical trials of this type of molecularly targeted agent. Finally, we discuss the biomarkers and surrogate pharmacodynamic endpoint assays currently available to chart the efficacy of apoptosis-inducing anticancer therapy. © 2004 Elsevier B.V. All rights reserved.
Original languageEnglish
Pages (from-to)53-66
Number of pages13
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Issue number1
Publication statusPublished - 10 Dec 2004


  • Apoptosis-targeted therapy
  • Assay validation
  • Biomarker
  • Early clinical trial
  • Pharmacodynamic assay
  • Quality assurance


Dive into the research topics of 'Apoptosis pathway-targeted drugs - From the bench to the clinic'. Together they form a unique fingerprint.

Cite this